Cogent Biosciences, Inc.
COGT
$11.40
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.90M | 11.69M | 11.80M | 10.09M | 9.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.93M | 73.73M | 75.41M | 64.39M | 62.40M |
| Operating Income | -74.93M | -73.73M | -75.41M | -64.39M | -62.40M |
| Income Before Tax | -71.99M | -67.93M | -70.63M | -58.95M | -58.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.99M | -67.93M | -70.63M | -58.95M | -58.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.99M | -67.93M | -70.63M | -58.95M | -58.35M |
| EBIT | -74.93M | -73.73M | -75.41M | -64.39M | -62.40M |
| EBITDA | -74.29M | -73.11M | -74.79M | -63.78M | -61.81M |
| EPS Basic | -0.63 | -0.61 | -0.64 | -0.59 | -719.50 |
| Normalized Basic EPS | -0.40 | -0.35 | -0.40 | -0.37 | -449.69 |
| EPS Diluted | -0.63 | -0.61 | -0.64 | -0.59 | -719.50 |
| Normalized Diluted EPS | -0.40 | -0.35 | -0.40 | -0.37 | -449.69 |
| Average Basic Shares Outstanding | 113.38M | 111.45M | 110.17M | 99.24M | 81.10K |
| Average Diluted Shares Outstanding | 113.38M | 111.45M | 110.17M | 99.24M | 81.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |